Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00

Taysha Gene Therapies (NASDAQ:TSHA) had its price target lifted by Canaccord Genuity Group from $6.00 to $8.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock.

TSHA has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Down 9.3 %

Shares of TSHA opened at $2.06 on Friday. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The company has a market capitalization of $422.18 million, a price-to-earnings ratio of 3.27 and a beta of 0.44. The stock’s 50-day moving average price is $1.98 and its 200-day moving average price is $2.38. The company has a quick ratio of 5.22, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC increased its holdings in Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after purchasing an additional 14,294,445 shares during the period. Artal Group S.A. increased its holdings in Taysha Gene Therapies by 0.7% during the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after purchasing an additional 24,444 shares during the period. Geode Capital Management LLC increased its holdings in Taysha Gene Therapies by 23.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after purchasing an additional 682,273 shares during the period. State Street Corp increased its holdings in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after purchasing an additional 150,647 shares during the period. Finally, StemPoint Capital LP purchased a new stake in Taysha Gene Therapies during the 1st quarter worth about $3,122,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.